Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

NCT01450761 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1351

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Placebo matching Ipilimumab
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb